Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 3;219(7):e20201963. doi: 10.1084/jem.20201963

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Boieri et al.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 9. — Loss of TSLP expression in human breast cancer cells is associated with cancer progression and worse survival outcomes. (A) Immunofluorescence staining for TSLP in human breast tissue at three stages of cancer development. Note the complete loss of TSLP in invasive carcinoma (scale bar: 100 μm). (B) Box plot of TSLP expression in normal mammary glands versus breast cancers across TCGA/GTEx datasets (one-way ANOVA, Gene Expression Profiling Interactive Analysis database). TPM, transcript count per million. (C) TSLP RNA in situ hybridization showing TSLP expression in the breast cancer (upper panel) compared with its matched adjacent normal tissue (lower panel). Note that the normal mammary epithelial cells are the dominant source of TSLP transcripts in the breast (scale bar: 100 μm). (D) Normalized TSLP protein levels measured with ELISA in the paired samples of breast cancer and adjacent normal breast tissue from 28 patients with primary breast cancer (Wilcoxon test). (E) Overall survival of patients with basal-like, luminal A, luminal B, and HER2 breast cancers divided based on high (top 30%, n = 234) and low (bottom 30%, n = 234) tumor TSLP expression levels in TCGA (log-rank test, Gene Expression Profiling Interactive Analysis database). (F) Disease-free survival of patients with basal-like, luminal A, luminal B, and HER2 breast cancers divided based on high (top 30%, n = 234) and low (bottom 30%, n = 234) tumor TSLP expression levels in TCGA (log-rank test, Gene Expression Profiling Interactive Analysis database). All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.